December 9, 2020 11:21 AM ESTUpdated December 11, 03:06 PM

Updated: News briefing: Assembly Bio scraps microbiome programs; InveniAI, Kyowa Kirin expand partnership to focus on novel targets

Conner Mitchell

Jason Mast

Editor

More than a year after Gilead’s former R&D chief John McHutchison took the reins at Assembly Biosciences, the San Francisco, California-based company is pulling back …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: News briefing: Assembly Bio scraps microbiome programs; InveniAI, Kyowa Kirin expand partnership to focus on novel targets

Conner Mitchell

Jason Mast

Editor

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Up­dat­ed: News brief­ing: As­sem­bly Bio scraps mi­cro­bio­me pro­grams; In­ve­ni­AI, Ky­owa Kirin ex­pand part­ner­ship to fo­cus on nov­el tar­gets

Editor

Sign up to read this article for free.

more like this

Updated: News briefing: Assembly Bio scraps microbiome programs; InveniAI, Kyowa Kirin expand partnership to focus on novel targets